TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02545868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-PPV
Description: The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 23-PPV
Description: The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-PCV Booster
Description: The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Vaccine
Description: The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
Study: NCT04365036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: pegaspargase, 2000U/m2, d1, intravenous drip
Study: NCT02545868

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: KLH
Description: KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCR
Description: OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.

Intervention type: DRUG
Group type: OTHER
Intervention: OCR
Description: OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
Study: NCT04365036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: pegaspargase, 2000U/m2, d1, intravenous drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine, 1000mg/m2, d1,d8, intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine, 1000mg/m2, d1,d8, intravenous drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin, 130mg/m2, d1, intravenous drip,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin, 130mg/m2, d1, intravenous drip,

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive intensity-modulated radiotherapy (IMRT)
Description: Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive intensity-modulated radiotherapy (IMRT)
Description: Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
Study: NCT02545868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TT Vaccine
Description: The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TT Vaccine
Description: The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
Study: NCT01652872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
Study: NCT00426023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A 0,05% eye drop
Description: Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketotifen fumarate 0.025% eye drops
Description: ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
Study: NCT04704414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exophthalmos measurement
Description: Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
Study: NCT01557946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: citalopram 20-40 mg daily
Study: NCT01793857

Intervention type: OTHER
Intervention: Data collection
Description: Paper questionnaire
Study: NCT02567422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT00457431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild therapeutic hypothermia
Description: Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
Study: NCT01822964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: targeted brain cooling (33°C) by RhinoChill device
Description: targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
Study: NCT02567422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03296189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 10 mls normal saline
Study: NCT03274700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin.
Description: Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
Study: NCT01038921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 8 mg dose of Melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01079221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity knee-extensor training
Description: High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
Study: NCT01978119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSC
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSC
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
Study: NCT01422759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 50-100 mg PO BID (X 12 weeks)
Study: NCT02352493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-CC5
Description: Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: calculated volume to match active comparator
Study: NCT02322606

Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5 mg tablet, TAK-137 placebo tablet

Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5 mg tablet, TAK-137 placebo tablet

Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet

Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5mg tablet, TAK-137 placebo tablet

Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5 mg tablet, TAK-137 placebo tablet

Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5mg tablet, TAK-137 placebo tablet
Study: NCT03590977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: licorice extract mouthwash
Description: mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chlorohexidine mouthwash
Description: mouth wash that contains chlorohexidine as an active component
Study: NCT00591812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ComPreSs Distal Femoral Replacement System.
Description: ComPreSs system of intramedullary fixation along with the Finn Knee system
Study: NCT03632356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care Intervention (STEP)
Description: A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening only
Description: Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
Study: NCT03749226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam lysine
Description: nebulization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo
Description: Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CombiHaler
Description: The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
Study: NCT02889549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
Study: NCT00477711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab, cisplatin, capecitabine
Description: Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
Study: NCT02721589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)
Study: NCT01822964

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - current clinical practice, no cooling
Study: NCT04264988

Intervention type: PROCEDURE
Intervention: Stopping of pelvic bleeding via several surgical methods
Description: Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
Study: NCT02721589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)
Study: NCT03957122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6
Study: NCT02223390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving AIDS Care after Trauma (ImpACT)
Study: NCT03395795

Intervention type: DEVICE
Group type: OTHER
Intervention: NAVA
Description: The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording.
Study: NCT03495336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee abstention phase
Description: no coffee consumption for 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee abstention phase
Description: no coffee consumption for 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LR Coffee consumption
Description: for 4 weeks participants consumed only LR Turkish coffee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DR Coffee consumption
Description: for 4 weeks participants consumed only DR Turkish coffee
Study: NCT00651989

Intervention type: OTHER
Intervention: optical coherence tomography foveal thickness measurement
Description: In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
Study: NCT01994486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir and Sofosbuvir
Description: All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
Study: NCT00085410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT02838602

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ions therapy
Description: External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Advanced external radiotherapy by Xrays or protons
Description: Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
Study: NCT04295941

Intervention type: DRUG
Intervention: TraZODone Hydrochloride 300 MG
Description: Oral administration of Trazodone once-a-day.
Study: NCT04511715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Bevacizumab IVB
Description: Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Follow-up with regular examination for determination of DR progression
Description: regular examination for determination of DR progression
Study: NCT03965260

Intervention type: BIOLOGICAL
Intervention: Bacterial samples from blood or peritoneal liquids
Description: For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance.
Study: NCT04344821

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curves Calcium
Description: Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)
Study: NCT02792088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir 150mg
Description: Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 300mg
Description: Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.